Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate
Scrip Pricing Debate

Beyond COVID-19 Spending Growth, Biosimilars Slowed Growth In Other Categories

The COVID-19 windfall meant a 12% rise in spending on medicines in the US in 2021 versus 2020, but just 5% excluding COVID, which is expected to fall to 1%-4% compound annual growth through 2026.

Biosimilars Coronavirus COVID-19

Civica Takes On The Challenge Of Insulin Affordability

The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.

Biosimilars Pricing Strategies

Sanofi US Net Prices Declined In 2021, But Less So Than In Prior Years

Sanofi's US net drug prices declined 1.3% in 2021, the smallest decline in six years of publicly disclosing aggregate list and net price information.

Pricing Strategies Pricing Debate

Lilly/Innovent Experience Show Hurdles Remaining For Chinese PD-1 Inhibitors

China has fielded several homegrown checkpoint inhibitors, using lower cost as an argument for the US market, but sintilimab – a key test case – has underscored FDA skepticism.

Cancer ImmunoOncology

Scrip Asks...What Does 2022 Hold For Biopharma? Part 1: Markets, Competition And Business Strategy

Biopharma industry leaders highlight key concerns and opportunities across production, supply chain and commercial operations. Business transformation is top of mind for many, perhaps unsurprisingly following two years of rapid and mostly successful adaptation to the strictures of the COVID-19 pandemic.

Scrip Asks Business Strategies

Stock Watch: When Governments Step In

Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.

Stock Watch Advisory Committees

Stock Watch: The Pandemic Brings Christmas Presents

While the Omicron variant does not bode well for 2022, vaccine boosters and oral antivirals are the products from the pharmaceutical sector that should keep on giving. Even if partisan analysts choose to forget them.

Stock Watch Pricing Debate

Lilly Looks To Volume-Driven Growth In Decade Ahead

CEO Dave Ricks told investors Lilly will succeed via volume-driven growth of nine key products launched since 2019, which its commitment to lower prices will facilitate.

Business Strategies Pricing Debate

Plans For US Government To Negotiate Prices Not A Done Deal, Says AZ’s Dobber

While Democrat politicians - and most voters- want to see drug pricing negotiations introduced in the US for the first time, pharma leaders believe a deal on out of pocket costs will be agreed instead.

Commercial Companies

AbbVie And Biogen Make ICER's Unsupported Price Increase List Three Years Running

ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.

Pricing Strategies Pricing Debate

Q3 Review: Editor’s Picks Of Scrip's Top Stories

From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.

Commercial Companies

Stock Watch: Third-Quarter Earnings Season – The New Endemic Normal

With the latest Delta variant wave in the rear-view mirror, vaccine and antiviral sales, and their impact on full-year guidance, are likely to remain the big swing factors in third-quarter earnings season.

Stock Watch Sales & Earnings
See All
UsernamePublicRestriction

Register